Advisory Board 11th Executive Congress on Translational Medicine, Biotech Innovation & Clinical Strategy
The Advisory Board supports the strategic direction, clinical relevance, scientific quality, and executive-level dialogue of ECTMBICS 2027, bringing together global perspectives across translational medicine, biotechnology, clinical research, pharma strategy, digital health, regulatory science, and healthcare commercialisation.
Participation is by invitation and based on senior expertise, global relevance, scientific leadership, clinical impact, and industry contribution.
Advisory Board Members
A diversified international advisory panel representing leading expertise across biomedical innovation, gene editing, clinical research, digital medicine, regulatory science, healthcare systems, and pharma strategy.
Dr. Robert Langer
MIT, USA
Biotechnology, biomaterials, and drug delivery innovation.
Dr. Jennifer Doudna
UC Berkeley, USA
CRISPR gene editing and genome engineering.
Dr. Soumya Swaminathan
India
Global health, clinical research, and public health strategy.
Prof. Carl June
University of Pennsylvania, USA
CAR-T cell therapy and translational immunotherapy.
Dr. Özlem Türeci
BioNTech, Germany
mRNA therapeutics, oncology, and biotech leadership.
Dr. Katalin Karikó
Hungary / USA
mRNA science, vaccines, and therapeutic innovation.
Dr. Atul Gawande
Harvard, USA
Healthcare systems, surgery, public health, and care delivery.
Dr. Eric Topol
Scripps Research, USA
Digital medicine, AI in healthcare, and genomic medicine.
Prof. Patrick Vallance
United Kingdom
Clinical research, pharma strategy, and science policy.
Dr. Devi Shetty
Narayana Health, India
Healthcare innovation, cardiac care, and access models.
Dr. Feng Zhang
Broad Institute, USA
Genome editing, CRISPR systems, and molecular innovation.
Prof. Sir John Bell
University of Oxford, UK
Translational medicine, biomedical strategy, and innovation policy.
Dr. Margaret Hamburg
USA
Regulatory science, public health, and medical product oversight.
Dr. Ruxandra Draghia-Akli
Europe
Pharma innovation, R&D strategy, and biomedical leadership.
Interested in joining the Advisory Board?
Advisory Board participation is generally by invitation. Senior experts may send a short profile outlining their leadership background and areas of contribution.